We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

17 hedge funds and large institutions have $38.1M invested in GT Biopharma in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

10,838% more capital invested

Capital invested by funds: $349K → $38.1M (+$37.8M)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

44.54% more ownership

Funds ownership: 5.47% → 50.01% (+45%)

0% more funds holding

Funds holding: 17 → 17 (0)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$3.5M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$67.9K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$35.8K
4
UBS Group
UBS Group
Switzerland
+$28.5K
5
Bank of America
Bank of America
North Carolina
+$36

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$35.8K
2
BlackRock
BlackRock
New York
-$1.3K
3
TRCT
Tower Research Capital (TRC)
New York
-$458
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$271
5
Osaic Holdings
Osaic Holdings
Arizona
-$72
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$37.8M +$3.5M +978,358 New
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$93.2K +$35.8K +10,000 +50%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$53.7K +$67.9K +18,984 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$31.7K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$29.7K -$35.8K -10,008 -49%
Wells Fargo
6
Wells Fargo
California
$28.3K -$39 -11 -0.1%
BlackRock
7
BlackRock
New York
$27.6K -$1.3K -364 -4%
UBS Group
8
UBS Group
Switzerland
$25.4K +$28.5K +7,958 +778%
TRCT
9
Tower Research Capital (TRC)
New York
$6.15K -$458 -128 -6%
Morgan Stanley
10
Morgan Stanley
New York
$753 – – –
Bank of America
11
Bank of America
North Carolina
$76 +$36 +10 +59%
Osaic Holdings
12
Osaic Holdings
Arizona
$33 -$72 -20 -63%
BBPWM
13
Blue Bell Private Wealth Management
Pennsylvania
$28 – – –
BNP Paribas Financial Markets
14
BNP Paribas Financial Markets
France
$17 – – –
FRA
15
Front Row Advisors
California
$3 – – –
JP Morgan Chase
16
JP Morgan Chase
New York
$3 – – –
Fidelity Investments
17
Fidelity Investments
Massachusetts
– -$271 -61 Closed

GTBP Hedge Fund Activity: Q2 2024 in Review

17 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2024, worth a combined $38.1M — up 10,838% from $349K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new GTBP positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.

The largest buyer was DekaBank Deutsche Girozentrale, opening a new position worth an estimated $3.5M. The largest seller was Vanguard Group, cutting an estimated $35.8K.

  • 17 institutional investors held GT Biopharma (GTBP) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $38.1M of GT Biopharma stock for Q2 2024, up 10,838% quarter-over-quarter.
  • 2 funds opened new GT Biopharma positions in Q2 2024 and 1 closed out, a net change of +1 holder.
  • The largest GT Biopharma buyer in Q2 2024 was DekaBank Deutsche Girozentrale, an estimated $3.5M added.
  • The largest GT Biopharma seller in Q2 2024 was Vanguard Group, an estimated $35.8K sold.

Based on aggregated 13F filings for Q2 2024.